Pacer Advisors’s CytomX Therapeutics CTMX Stock Holding History

Pacer Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14K	Buy	+3,697	New	+$14.1K	﹤0.01%	2308
2021 Q2	–	Sell	-3,806	Closed	-$29K	–	1443
2021 Q1	$29K	Buy	3,806 +1,000	+36%	+$7.92K	﹤0.01%	1481
2020 Q4	$18K	Buy	2,806 +366	+15%	+$2.62K	﹤0.01%	1487
2020 Q3	$16K	Buy	+2,440	New	+$18.1K	﹤0.01%	1362
2018 Q4	–	Sell	-4,431	Closed	-$82K	–	659
2018 Q3	$82K	Buy	+4,431	New	+$101K	﹤0.01%	1111
2018 Q1	–	Sell	-525	Closed	-$11K	–	1057
2017 Q4	$11K	Buy	+525	New	+$10.9K	﹤0.01%	1138

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Pacer Advisors's CTMX Position: Q2 2026 in Review

Pacer Advisors opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 3,697 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #2308 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in CTMX as recently as Q1 2021.

Pacer Advisors first reported a position in CTMX in Q4 2017 and has held it in 6 quarters since. The position peaked at $82K in Q3 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Pacer Advisors held 3,697 shares of CytomX Therapeutics worth $14K as of Q2 2026.
CytomX Therapeutics was a new Pacer Advisors position in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2308 holding.
Pacer Advisors first reported a position in CytomX Therapeutics in Q4 2017 and has held it in 6 quarters since.
Pacer Advisors's CytomX Therapeutics position peaked at $82K in Q3 2018.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.